전체 프로그램

ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-6 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved31 programs
AntibodyLimited DatastaleBioXcel Therapeutics IncPhase 2

pembrolizumab (Keytruda, BXCL701 plus Pembrolizumab)

Prostate Cancer; Neuroendocrine Tumors · Prostate Cancer

#ProstateCancer#Antibody#Phase2#monoclonal-antibody#NeuroendocrineTumors+1
Trials 1Status Active
CGTLimited DatastaleTceleron Therapeutics, Inc.Phase 1

CART-PSMA-TGFβRDN (CART-PSMA-TGFβRDN)

Metastatic Castration-resistant Prostate Cancer · PSMA

#PSMA#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Discontinued
AntibodyLimited DatastaleCorvus Pharmaceuticals, Inc.Phase 1

atezolizumab (Tecentriq, Ciforadenant + atezolizumab)

Renal Cell Cancer; Metastatic Castration Resistant Prostate Cancer · Renal Cell Cancer

#RenalCellCancer#Antibody#Phase1#monoclonal-antibody#MetastaticCastrationResistantPro+1
Trials 1Status Active
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin（RC48-ADC）)

Metastatic Castration-resistant Prostate Cancer · Metastatic Castration-resistant Prostate

#MetastaticCastration-resistantPr#ADC#Phase2#antibody-drug-conjugate#RemeGen
Trials 1Status Active
CGTLimited DatastaleBioray LaboratoriesPhase 1

PD1-PSMA-CART cells (PD1-PSMA-CART cells)

Castrate-Resistant Prostate Cancer · PSMA

#PSMA#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleShanghai Changzheng HospitalPhase 1

BRL-302 (PSMA-UCAR T, PSMA-UCAR T (BRL-302))

Metastatic Prostate Cancer; Castration-resistant Prostate Cancer · PSMA

#PSMA#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
AntibodyLimited DatastaleRegeneronPhase 2

REGN15505+Cemiplimab (REGN15505+Cemiplimab)

Metastatic Castration-Resistant Prostate Cancer (mCRPC); Clear Cell Renal Cell Carcinoma (ccRCC) · Metastatic Castration-Resistant Prostate

#MetastaticCastration-ResistantPr#Antibody#Phase2#monoclonal-antibody#ClearCellRenalCellCarcinomaccRCC+1
Trials 1Status Recruiting
AntibodyLimited DatastaleInstitut Cancerologie de l'OuestPhase 2

durvalumab (Imfinzi, SBRT + Durvalumab)

Node; Prostate; Bone Metastases · Node; Prostate

#NodeProstate#Antibody#Phase2#monoclonal-antibody#Node+3
Trials 1Status Recruiting
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 1

T-cell receptor alternate reading frame protein (TARP, T-cell receptor alternate reading frame protein, T-cell receptor alternate reading frame protein (TARP) dendritic cell vaccine)

Prostate Specific Antigens; Prostate Neoplasms · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 1

T-cell receptor alternate reading frame protein (TARP, T-cell receptor alternate reading frame protein, T-cell receptor alternate reading frame protein (TARP) peptide vaccine)

Prostate Specific Antigens; Prostate Neoplasms · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleAvenCell Europe GmbHPhase 1

UniCAR02-T-pPSMA (UniCAR02-T-pPSMA)

Prostate Cancer · PSMA

#PSMA#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Discontinued

2 / 2 pages

← PreviousNext →